Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MultiCenter, Open-Label Phase 1 Study of DS-1205c in Combination with GEFITINIB in SUBJECTS with Metastatic or Unresectable egfr mutant Non Small Cell Lung Cancer

Next Previous
Trial Profile

A MultiCenter, Open-Label Phase 1 Study of DS-1205c in Combination with GEFITINIB in SUBJECTS with Metastatic or Unresectable egfr mutant Non Small Cell Lung Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 329 (Primary) ; Gefitinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 21 Sep 2020 According to results presented at the 45th European Society for Medical Oncology Congress, Dose Escalation has been completed with the result that RDE is 800 mg BID, and updated clinical and biomarker data will be presented.
    • 21 Sep 2020 Status changed to active, no longer recruiting, according to results presented at the 45th European Society for Medical Oncology Congress
    • 21 Sep 2020 Results of dose escalation part of this trial presented at the 45th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top